Cover Image
Market Research Report

Latin America, Middle East & Africa Autoimmune Disease Therapeutics Market (2019-2025)

Published by KBV Research Product code 906237
Published Content info 106 Pages
Delivery time: 1-2 business days
Price
Back to Top
Latin America, Middle East & Africa Autoimmune Disease Therapeutics Market (2019-2025)
Published: July 31, 2019 Content info: 106 Pages
Description

The Latin America, Middle East and Africa Autoimmune Disease Therapeutics Market would witness market growth of 5.38% CAGR during the forecast period (2019-2025).

Autoimmune diseases are usually chronic and there's no curative treatment for them. Dermatomyositis, Hashimoto's disease of type 1 diabetes, Sjogren's syndrome, Psoriasis are some examples of autoimmune diseases. Systemic treatment of autoimmune diseases and localized treatment of autoimmune disease are two kinds of treatments for autoimmune disease.

The accelerated acceptance of autoimmune disease therapeutics expanded wide accessibility of sophisticated therapy, and an increase in the number of research and development operations are collectively driving the market growth. High original expenses linked to sophisticated therapies, however, restrict the market growth. On the other side, the powerful existence of pipeline drugs and possibilities in emerging economies creates new sector routes.

Based on Indication, the market is segmented into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Other Indications. Based on Drug Class, the market is segmented into Anti-Inflammatory, Anti-Hyperglycemics, NSAIDs (Nonsteroidal anti-inflammatory drugs), Interferons and Other Drugs. Based on the Distribution Channel, the market is segmented into Hospital Pharmacy, Online and Retail Pharmacies & Drug Stores. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, Bio-Rad Laboratories, Inc., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, AbbVie, Inc., Amgen, Inc. and Novartis.

Scope of the Study

Market Segmentation:

By Indication

  • Rheumatic Disease
  • Diabetes
  • Multiple Sclerosis
  • Inflammatory Bowel Disease
  • Other Indications

By Drug Class

  • Anti-Inflammatory
  • Anti-Hyperglycemics
  • NSAIDs
  • Interferons
  • Other Drugs

By Distribution Channel

  • Hospital Pharmacy
  • Online
  • Retail Pharmacies and Drug Stores

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled:

  • ABBOTT Laboratories
  • Bio-Rad Laboratories, Inc.
  • Johnson and Johnson
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Bayer AG
  • AbbVie, Inc.
  • Amgen, Inc.
  • Novartis AG

Unique Offerings from KBV Research:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA Autoimmune Disease Therapeutics Market, by Indication
    • 1.4.2 LAMEA Autoimmune Disease Therapeutics Market, by Drug Class
    • 1.4.3 LAMEA Autoimmune Disease Therapeutics Market, by Distribution Channel
    • 1.4.4 LAMEA Autoimmune Disease Therapeutics Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. LAMEA Autoimmune Disease Therapeutics Market by Indication

  • 3.1 LAMEA Rheumatic Disease Market by Country
  • 3.2 LAMEA Diabetes Market by Country
  • 3.3 LAMEA Multiple Sclerosis Market by Country
  • 3.4 LAMEA Inflammatory Bowel Disease Market by Country
  • 3.5 LAMEA Other Indications Market by Country

Chapter 4. LAMEA Autoimmune Disease Therapeutics Market by Drug Class

  • 4.1 LAMEA Anti-Inflammatory Market by Country
  • 4.2 LAMEA Anti-Hyperglycemics Market by Country
  • 4.3 LAMEA NSAIDs Market by Country
  • 4.4 LAMEA Interferons Market by Country
  • 4.5 LAMEA Other Drugs Market by Country

Chapter 5. LAMEA Autoimmune Disease Therapeutics Market by Distribution Channel

  • 5.1 LAMEA Hospital Pharmacy Market by Country
  • 5.2 LAMEA Online Market by Country
  • 5.3 LAMEA Retail Pharmacies and Drug Stores Market by Country

Chapter 6. LAMEA Autoimmune Disease Therapeutics Market by Country

  • 6.1 Brazil Autoimmune Disease Therapeutics Market
    • 6.1.1 Brazil Autoimmune Disease Therapeutics Market by Indication
    • 6.1.2 Brazil Autoimmune Disease Therapeutics Market by Drug Class
    • 6.1.3 Brazil Autoimmune Disease Therapeutics Market by Distribution Channel
  • 6.2 Argentina Autoimmune Disease Therapeutics Market
    • 6.2.1 Argentina Autoimmune Disease Therapeutics Market by Indication
    • 6.2.2 Argentina Autoimmune Disease Therapeutics Market by Drug Class
    • 6.2.3 Argentina Autoimmune Disease Therapeutics Market by Distribution Channel
  • 6.3 UAE Autoimmune Disease Therapeutics Market
    • 6.3.1 UAE Autoimmune Disease Therapeutics Market by Indication
    • 6.3.2 UAE Autoimmune Disease Therapeutics Market by Drug Class
    • 6.3.3 UAE Autoimmune Disease Therapeutics Market by Distribution Channel
  • 6.4 Saudi Arabia Autoimmune Disease Therapeutics Market
    • 6.4.1 Saudi Arabia Autoimmune Disease Therapeutics Market by Indication
    • 6.4.2 Saudi Arabia Autoimmune Disease Therapeutics Market by Drug Class
    • 6.4.3 Saudi Arabia Autoimmune Disease Therapeutics Market by Distribution Channel
  • 6.5 South Africa Autoimmune Disease Therapeutics Market
    • 6.5.1 South Africa Autoimmune Disease Therapeutics Market by Indication
    • 6.5.2 South Africa Autoimmune Disease Therapeutics Market by Drug Class
    • 6.5.3 South Africa Autoimmune Disease Therapeutics Market by Distribution Channel
  • 6.6 Nigeria Autoimmune Disease Therapeutics Market
    • 6.6.1 Nigeria Autoimmune Disease Therapeutics Market by Indication
    • 6.6.2 Nigeria Autoimmune Disease Therapeutics Market by Drug Class
    • 6.6.3 Nigeria Autoimmune Disease Therapeutics Market by Distribution Channel
  • 6.7 Rest of LAMEA Autoimmune Disease Therapeutics Market
    • 6.7.1 Rest of LAMEA Autoimmune Disease Therapeutics Market by Indication
    • 6.7.2 Rest of LAMEA Autoimmune Disease Therapeutics Market by Drug Class
    • 6.7.3 Rest of LAMEA Autoimmune Disease Therapeutics Market by Distribution Channel

Chapter 7. Company Profiles

  • 7.1 ABBOTT Laboratories
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental and Regional Analysis
    • 7.1.4 Research & Development Expense
  • 7.2 Bio-Rad Laboratories, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 Johnson and Johnson
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental &Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.1 Recent strategies and developments:
      • 7.3.1.1 Collaborations, partnerships and agreements:
  • 7.4 GlaxoSmithKline PLC (GSK)
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Segmental and Regional Analysis
    • 7.4.4 Research & Development Expense
    • 7.4.5 Recent strategies and developments:
      • 7.4.5.1 Acquisition and mergers:
      • 7.4.5.2 Collaborations, partnerships and agreements:
      • 7.4.5.3 Product launches:
  • 7.5 Pfizer, Inc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental and Regional Analysis
    • 7.5.4 Research & Development Expense
    • 7.5.5 Recent strategies and developments:
      • 7.5.5.1 Collaborations, partnerships and agreements:
      • 7.5.5.2 Approval:
  • 7.6 Merck & Co., Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Segmental and Regional Analysis
    • 7.6.4 Research & Development Expenses
    • 7.6.5 Recent strategies and developments:
      • 7.6.5.1 Collaborations, partnerships and agreements:
      • 7.6.5.2 Acquisition and mergers:
  • 7.7 Bayer AG (Bayer Schering Pharma AG)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
    • 7.7.5 Recent strategies and developments:
      • 7.7.5.1 Collaborations, partnerships and agreements:
  • 7.8 AbbVie, Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Regional Analysis
    • 7.8.4 Research & Development Expense
    • 7.8.5 Recent strategies and developments:
      • 7.8.5.1 Collaborations, partnerships and agreements:
  • 7.9 Amgen, Inc.
    • 7.9.1 Company overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Regional Analysis
    • 7.9.4 Research & Development Expense
    • 7.9.5 Recent strategies and developments:
      • 7.9.5.1 Product launches:
      • 7.9.5.2 Collaborations, partnerships and agreements:
  • 7.1 Novartis AG
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense
    • 7.10.5 Recent strategies and developments:
      • 7.10.5.1 Acquisition and mergers:
      • 7.10.5.2 Collaborations, partnerships and agreements:

LIST OF TABLES

  • TABLE 1 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 2 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 3 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 4 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 5 LAMEA RHEUMATIC DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 6 LAMEA RHEUMATIC DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 7 LAMEA DIABETES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 8 LAMEA DIABETES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 9 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 10 LAMEA MULTIPLE SCLEROSIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 11 LAMEA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 12 LAMEA INFLAMMATORY BOWEL DISEASE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 13 LAMEA OTHER INDICATIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 14 LAMEA OTHER INDICATIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 15 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 16 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 17 LAMEA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 18 LAMEA ANTI-INFLAMMATORY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 19 LAMEA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 20 LAMEA ANTI-HYPERGLYCEMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 21 LAMEA NSAIDS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 22 LAMEA NSAIDS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 23 LAMEA INTERFERONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 24 LAMEA INTERFERONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 25 LAMEA OTHER DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 26 LAMEA OTHER DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 27 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 28 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 29 LAMEA HOSPITAL PHARMACY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 30 LAMEA HOSPITAL PHARMACY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 31 LAMEA ONLINE MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 32 LAMEA ONLINE MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 33 LAMEA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 34 LAMEA RETAIL PHARMACIES AND DRUG STORES MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 35 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 36 LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 37 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 38 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 39 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 40 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 41 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 42 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 43 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 44 BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 45 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 46 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 47 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 48 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 49 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 50 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 51 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 52 ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 53 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 54 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 55 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 56 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 57 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 58 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 59 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 60 UAE AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 61 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 62 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 63 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 64 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 65 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 66 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 67 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 68 SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 69 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 70 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 71 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 72 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 73 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 74 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 75 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 76 SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 77 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 78 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 79 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 80 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 81 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 82 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 83 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 84 NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 85 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 86 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 87 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 88 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 89 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2015 - 2018, USD MILLION
  • TABLE 90 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DRUG CLASS, 2019 - 2025, USD MILLION
  • TABLE 91 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2015 - 2018, USD MILLION
  • TABLE 92 REST OF LAMEA AUTOIMMUNE DISEASE THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2019 - 2025, USD MILLION
  • TABLE 93 KEY INFORMATION - ABBOTT LABORATORIES
  • TABLE 94 KEY INFORMATION - BIO-RAD LABORATORIES, INC.
  • TABLE 95 KEY INFORMATION -JOHNSON AND JOHNSON
  • TABLE 96 KEY INFORMATION - GLAXOSMITHKLINE PLC (GSK)
  • TABLE 97 KEY INFORMATION - PFIZER, INC.
  • TABLE 98 KEY INFORMATION - MERCK & CO., INC.
  • TABLE 99 KEY INFORMATION - BAYER AG
  • TABLE 100 KEY INFORMATION - ABBVIE, INC.
  • TABLE 101 KEY INFORMATION - AMGEN, INC.
  • TABLE 102 KEY INFORMATION - NOVARTIS AG

LIST OF FIGURES

  • FIG 1 METHODOLOGY FOR THE RESEARCH
Back to Top